India 
USA
UK
South Africa
Australia
Philippines
Germany
Netherlands
Mexico
Brazil
Canada
Consolidated
Earnings Call audio Unaudited
Unaudited
Q4
(Jan – Mar)
Audited
Q3
(Oct – Dec)
Unaudited
Q2
(July – Sep)
Unaudited
Unaudited
Q4
(Jan – Mar)
Audited
Q3
(Oct – Dec)
Unaudited
Q2
(July – Sep)
Unaudited
Q1
(April – June)
Unaudited
Q4
(Jan – Mar)
Audited
Q2
(July – Sep)
Published on 30 Sep 2019
Unaudited
Q1
(April – June)
Published on 30 June 2019
Unaudited
-
FINANCIAL YEAR 2024
Tax Transparency Report (2 MB)DNV Assurance Certificate (IR) (226 KB)DNV Assurance Certificate (BRSR) (331 KB)Human Rights Assessment Declaration (125 KB) -
FINANCIAL YEAR 2023
S&P Global CSA Score 2023: 69/100 (52.2 KB )Tax Transparency Report (2 MB)Transition Risks Report (4 MB)TCFD Report (7.1 MB)Assurance Certificate (236 KB) -
-
-
FINANCIAL YEAR 2020
Download Low res (13.2MB)
- 2024
- 2023
- 2022
- 2021
- 2020
2024
2023
2022
2021- BSE / NSE Letter Schedule of Analyst Investors Meet.
- Appointment of Claus Jepsen as President, Global Specialty
- BSE / NSE Letter U.S. FDA Inspection of the Company’s Biotech Facility in Pune
- Bse / Nse Letter U.S. FDA Inspection of the Company’s Manufacturing Facility at Pithampur Unit-1.
- Bse / Nse Letter Schedule of Analyst Investors Meet.
- Appointment of CEO – Lupin Manufacturing Solutions.
- Business Transfer Agreement with Lupin Life Sciences Limited.
- BSE / NSE Acquisition Brands Sanofi.
- BSE / NSE Reg30 Settlement Agreement Glumetza.
- BSE / NSE Letter Somerset Regulation.
- Disclosure pursuant to Regulation 42 and 44 of SEBI.
- Disclosure pursuant to Regulation 30 of SEBI.
- BSE / NSE Re-launch of Mirabegron Extended-Release (ER) Tablets 25 mg in the United States.
- Bse / Nse Change In Directors.
- Order from Office of the Deputy Commissioner of State Tax, CT and GST Circle, Cuttack – I West Circle, Orissa.
- BSE/NSE Disclosure Letter-4.
- BSE/NSE Disclosure Letter-3.
- BSE/NSE Disclosure Letter-2.
- State tax intimation.
- Appointment of Chief Quality Officer.
- Income Tax intimation.
- Generic business carve out – Lupin Life Sciences Limited (LLSL).
- Letter rec’d regarding input tax credit Patna depot.
- Appointment of Chief Technical Officer.
- USFDA inspection at Aurangabad.
- Business Transfer Agreement with Lupin Manufacturing Solutions Limited (LMSL) – transaction complete.
- Acquisition of a portfolio of accretive established products in Europe and Canada.
- Business Transfer Agreement with LMSL
- Disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements).
- Disclosure pursuant to Regulation 30 of SEBI (Lupin Manufacturing Solutions Ltd)
- BSE-NSE-Letter-Disclosure pursuant to regulation 30 of SEBI.
- USFDA warning – Tarapur – Sept 29
- Brand acquisition from Boehringer Ingelheim International GmbH –
Aug 24 - USFDA EIR – Somerset – Jul 7
- USFDA audit – Tarapur – Apr 5
- Acquisition of portfolio of brands from Anglo-French Drugs & Industries Limited – Apr 1
- Acquisition of portfolio of brands of Anglo-French – Jan 18
-
Shareholder Services
-
Investor Relations
Subscribe for Investor updates